Growth Ledger

British Business Bank invests in life sciences

By Sari Oktaviani
·
Share:
Life sciences research laboratory.
Life sciences research laboratory.

The British Business Bank has invested £1.1 billion in the life sciences sector, including £832 million across 20 life science funds and £302 million in domestic scale-ups, to boost funding rounds and attract pension fund investments.

Recent investments include £25 million in Alchemab Therapeutics and £15 million in Cambridge university spinout T-Therapeutics.

In remarks, the bank’s chief investment officer, Leandros Kalisperas, said the bank must take an aggressive approach to financing life sciences to encourage more investment from pension funds. Currently, pension funds mostly allocate capital to property, with only £500 million going to private equity.

Investment Strategy

The bank is attempting to entice institutional investors, including signatories of the Mansion House accord, to unlock further pension capital for private assets and venture capital firms, including those that invest in life sciences.

The accord saw 11 of the UK’s top pension money managers commit to investing five per cent of their assets in private markets and unlisted equities by 2030. Kalisperas aims to communicate the possibilities for pension funds to get involved in life science innovation.

The sector faces challenges from acquisitions and relocations driven by foreign buyers. Some companies in the bank’s portfolio, such as ophthalmology biotech firm Eyebio, have been acquired by overseas entities like Merck & Co for up to $3 billion.

Industry Outlook

Chris Molloy, chief executive of the Bio Industry Association, believes the increased funding will enable promising businesses to scale and remain in the UK. Kalisperas expects investors to shift more capital into the sector as the AI cycle matures and its applications expand into real-world industries.

The bank has committed €58 million to Sofinnova Crossover Fund II, a Parisian-based fund backing European firms. Kalisperas emphasizes the need for European specialists to attract deep capital pools for UK companies, stating, “You can’t back venture in the UK by just investing in managers that only invest in the UK.”

The bank’s funding follows the National Wealth Fund’s £147 million debt financing for One North Quay in Canary Wharf, set to be one of Europe’s largest commercial science buildings. The project, expected to complete in 2028, also secured funding from Barclays and Emirates NBD, totaling £368.5 million.

Business, Innovation, Science and Trade Secretary, Jonathan Reynolds, affirmed the UK’s leadership in life sciences, stating that One North Quay will strengthen this position.

Leave a Reply

Your email address will not be published. Required fields are marked *